Neoadjuvant liposomal doxorubicin and carboplatin is effective and tolerable for the treatment of early stage triple negative breast cancer

被引：0
|
作者：
Chan, Nancy
Lu, Shou-en
Wang, Yue
Riedlinger, Gregory M.
Omene, Coral
George, Mridula
Malhotra, Jyoti
Kowzun, Maria
Eladoumikdachi, Firas G.
Potdevin, Lindsay B.
Kumar, Shicha
Matsuda, Kant
Desai, Shruti
Patel, Nayana
Toppmeyer, Deborah L.
Ganesan, Shridar
Hirshfield, Kim
机构：
来源：
CANCER RESEARCH | 2022年 / 82卷 / 04期
关键词：
D O I：
10.1158/1538-7445.SABCS21-P2-12-15
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P2-12-15
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Phase II neoadjuvant clinical trial of carboplatin and eribulin in women with triple negative early-stage breast cancer (NCT01372579)
    Virginia G. Kaklamani
    Jacqueline S. Jeruss
    Elisha Hughes
    Kalliopi Siziopikou
    Kirsten M. Timms
    Alexander Gutin
    Victor Abkevich
    Zaina Sangale
    Cara Solimeno
    Krystal L. Brown
    Joshua Jones
    Anne-Renee Hartman
    Caitlin Meservey
    Borko Jovanovic
    Irene Helenowski
    Seema A. Khan
    Kevin Bethke
    Nora Hansen
    Regina Uthe
    Sara Giordano
    Steven Rosen
    Kent Hoskins
    Jamie Von Roenn
    Sarika Jain
    Vamsi Parini
    William Gradishar
    Breast Cancer Research and Treatment, 2015, 151 : 629 - 638
  • [22] Triple-negative Breast Carcinoma: Carboplatin and Veliparib in the Neoadjuvant
    Lorenz, Judith
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2018, 78 (07)
  • [23] Update on the Treatment of Early-Stage Triple-Negative Breast Cancer
    Priyanka Sharma
    Current Treatment Options in Oncology, 2018, 19
  • [24] Update on the Treatment of Early-Stage Triple-Negative Breast Cancer
    Sharma, Priyanka
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2018, 19 (05)
  • [25] Cisplatin versus carboplatin in combination with paclitaxel as neoadjuvant regimen for triple negative breast cancer
    Huang, Liang
    Liu, Qi
    Chen, Sheng
    Shao, Zhiming
    ONCOTARGETS AND THERAPY, 2017, 10 : 5739 - 5744
  • [26] Neoadjuvant phase II trial with carboplatin and eribulin in triple negative breast cancer patients
    Giordano, S. B.
    Jeruss, J. S.
    Bethke, K. P.
    Hansen, N. M.
    Khan, S.
    Von Roenn, J.
    Rosen, S.
    Gradishar, W. L.
    Siziopikou, K. P.
    Meservey, C.
    Kaklamani, V.
    CANCER RESEARCH, 2013, 73
  • [27] Neoadjuvant carboplatin and docetaxel in locally advanced triple negative breast cancer: A Hispanic trial
    Gomez, Saul Campos
    Gomez, Karen Angelica Campos
    Garces, Marciela Garcia
    Morelos, Gladys
    Alvarez, Jesus Hernandez
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [28] Neoadjuvant treatment of triple negative breast cancer patients with docetaxel and carboplatin to assess anti-tumor activity
    Ademuyiwa, Foluso O.
    Rimawi, Mothaffar F.
    Summa, Tracy
    Luo, Jingqin
    Wang, Tao
    Suresh, Rama
    Peterson, Lindsay
    Naughton, Michael
    Frith, Ashley
    Hernandez-Aya, Leonel
    Weilbaecher, Katherine
    Ma, Cynthia
    Chaudhuri, Aadel A.
    Feng, Yang-Yang
    Skidmore, Zachary L.
    Griffith, Obi L.
    Griffith, Malachi
    Ellis, Matthew
    CANCER RESEARCH, 2020, 80 (04)
  • [29] Neoadjuvant Therapy in early triple-negative Breast Cancer strengthened
    Klein, Friederike
    DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2025, 150 (07)
  • [30] De-escalating treatment with neoadjuvant chemotherapy in early triple-negative breast cancer
    Murillo, Serafin Morales
    Cudos, Ariadna Gasol
    Der-Abrain, Noemi Tuset
    CANCER RESEARCH, 2024, 84 (09)
12345